Literature DB >> 28534116

Myeloid neoplasms with germ line RUNX1 mutation.

Yoshihiro Hayashi1,2, Yuka Harada3, Gang Huang2, Hironori Harada4.   

Abstract

Familial platelet disorder with propensity to myeloid malignancies (FPD/AML) is an autosomal dominant disorder characterized by quantitative and/or qualitative platelet defects with a tendency to develop a variety of hematological malignancies. Heterozygous germ line mutations in the RUNX1 gene are responsible genetic events for FPD/AML. Notably, about half of individuals in the family with germ line mutations in RUNX1 develop overt hematological malignancies. The latency is also relatively long as an average age at diagnosis is more than 30 years. Similar to what is observed in sporadic hematological malignancies, acquired additional genetic events cooperate with inherited RUNX1 mutations to progress the overt malignant phase. Reflecting recent increased awareness of hematological malignancies with germ line mutations, FPD/AML was added in the revised WHO 2016 classification. In this review, we provide an update on FPD/AML with recent clinical and experimental findings.

Entities:  

Keywords:  FPD/AML; FPD/MM; Germ line mutation; RUNX1

Mesh:

Substances:

Year:  2017        PMID: 28534116     DOI: 10.1007/s12185-017-2258-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  57 in total

1.  Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia.

Authors:  I Antony-Debré; N Duployez; M Bucci; S Geffroy; J-B Micol; A Renneville; N Boissel; N Dhédin; D Réa; B Nelken; C Berthon; T Leblanc; M-J Mozziconacci; R Favier; P G Heller; O Abdel-Wahab; H Raslova; V Latger-Cannard; C Preudhomme
Journal:  Leukemia       Date:  2015-08-28       Impact factor: 11.528

2.  Recurrent CDC25C mutations drive malignant transformation in FPD/AML.

Authors:  Akihide Yoshimi; Takashi Toya; Masahito Kawazu; Toshihide Ueno; Ayato Tsukamoto; Hiromitsu Iizuka; Masahiro Nakagawa; Yasuhito Nannya; Shunya Arai; Hironori Harada; Kensuke Usuki; Yasuhide Hayashi; Etsuro Ito; Keita Kirito; Hideaki Nakajima; Motoshi Ichikawa; Hiroyuki Mano; Mineo Kurokawa
Journal:  Nat Commun       Date:  2014-08-27       Impact factor: 14.919

3.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

4.  Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis.

Authors:  Hiromitsu Iizuka; Yuki Kagoya; Keisuke Kataoka; Akihide Yoshimi; Masashi Miyauchi; Kazuki Taoka; Keiki Kumano; Takashi Yamamoto; Akitsu Hotta; Shunya Arai; Mineo Kurokawa
Journal:  Exp Hematol       Date:  2015-06-11       Impact factor: 3.084

5.  AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis.

Authors:  Motoshi Ichikawa; Takashi Asai; Toshiki Saito; Sachiko Seo; Ieharu Yamazaki; Tetsuya Yamagata; Kinuko Mitani; Shigeru Chiba; Seishi Ogawa; Mineo Kurokawa; Hisamaru Hirai
Journal:  Nat Med       Date:  2004-02-15       Impact factor: 53.440

6.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

Review 7.  Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia.

Authors:  Peter Ganly; Logan C Walker; Christine M Morris
Journal:  Leuk Lymphoma       Date:  2004-01

8.  Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan.

Authors:  A Yoshimi; T Toya; Y Nannya; K Takaoka; K Kirito; E Ito; H Nakajima; Y Hayashi; T Takahashi; A Moriya-Saito; K Suzuki; H Harada; N Komatsu; K Usuki; M Ichikawa; M Kurokawa
Journal:  Ann Oncol       Date:  2016-02-15       Impact factor: 32.976

9.  Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0.

Authors:  Vladimir T Manchev; Hind Bouzid; Iléana Antony-Debré; Betty Leite; Guillaume Meurice; Nathalie Droin; Thomas Prebet; Régis T Costello; William Vainchenker; Isabelle Plo; M'boyba Diop; Elizabeth Macintyre; Vahid Asnafi; Rémi Favier; Véronique Baccini; Hana Raslova
Journal:  J Cell Mol Med       Date:  2016-12-20       Impact factor: 5.310

10.  Genetic basis of myeloid transformation in familial platelet disorder/acute myeloid leukemia patients with haploinsufficient RUNX1 allele.

Authors:  M Sakurai; H Kasahara; K Yoshida; A Yoshimi; H Kunimoto; N Watanabe; Y Shiraishi; K Chiba; H Tanaka; Y Harada; H Harada; T Kawakita; M Kurokawa; S Miyano; S Takahashi; S Ogawa; S Okamoto; H Nakajima
Journal:  Blood Cancer J       Date:  2016-02-05       Impact factor: 11.037

View more
  8 in total

Review 1.  Familial predisposition of myeloid malignancies: biological and clinical significance of recurrent germ line mutations.

Authors:  Hirotaka Matsui
Journal:  Int J Hematol       Date:  2017-06-19       Impact factor: 2.490

Review 2.  Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).

Authors:  Anna L Brown; Christopher N Hahn; Hamish S Scott
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 3.  Hematological Malignancies in Adults With a Family Predisposition.

Authors:  Tilmann Bochtler; Georg-Martin Haag; Sarah Schott; Matthias Kloor; Alwin Krämer; Carsten Müller-Tidow
Journal:  Dtsch Arztebl Int       Date:  2018-12-14       Impact factor: 5.594

Review 4.  Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective.

Authors:  Yoshihiro Hayashi; Yuka Harada; Hironori Harada
Journal:  Leukemia       Date:  2022-03-30       Impact factor: 11.528

5.  C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies.

Authors:  Kateřina Staňo Kozubík; Lenka Radová; Michaela Pešová; Kamila Réblová; Jakub Trizuljak; Karla Plevová; Veronika Fiamoli; Jaromír Gumulec; Helena Urbánková; Tomáš Szotkowski; Jiří Mayer; Šárka Pospíšilová; Michael Doubek
Journal:  Int J Hematol       Date:  2018-08-06       Impact factor: 2.490

6.  Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia.

Authors:  Hassan Awada; Yasunobu Nagata; Abhinav Goyal; Mohammad F Asad; Bhumika Patel; Cassandra M Hirsch; Teodora Kuzmanovic; Yihong Guan; Bartlomiej P Przychodzen; Mai Aly; Vera Adema; Wenyi Shen; Louis Williams; Aziz Nazha; Mohamed E Abazeed; Mikkael A Sekeres; Tomas Radivoyevitch; Torsten Haferlach; Babal K Jha; Valeria Visconte; Jaroslaw P Maciejewski
Journal:  Blood Adv       Date:  2019-02-12

Review 7.  Beyond Pathogenic RUNX1 Germline Variants: The Spectrum of Somatic Alterations in RUNX1-Familial Platelet Disorder with Predisposition to Hematologic Malignancies.

Authors:  Alisa Förster; Melanie Decker; Brigitte Schlegelberger; Tim Ripperger
Journal:  Cancers (Basel)       Date:  2022-07-14       Impact factor: 6.575

Review 8.  The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies.

Authors:  Asumi Yokota; Li Huo; Fengli Lan; Jianqiang Wu; Gang Huang
Journal:  Mol Cells       Date:  2020-02-29       Impact factor: 5.034

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.